BCHE and Alzheimer disease: In a validation study (57), a decline of 59 ms in focused attention (PoA) over 6 mo in patients with a diagnosis of very mild AD (>26 Mini-Mental State Examination) and treated with cholinesterase inhibitors has been considered as clinically important.